Company Encyclopedia
View More
name
MOLECULAR TEMPLATES INC
MTEMQ.US
1.930 T
MTEMQ.USMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking0/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE1994.38%A
    • Profit Margin-61.35%E
    • Gross Margin-844.41%E
  • Growth ScoreD
    • Revenue YoY-49.41%E
    • Net Profit YoY66.55%A
    • Total Assets YoY-24.82%E
    • Net Assets YoY181.94%A
  • Cash ScoreE
    • Cash Flow Margin-163.00%D
    • OCF YoY-49.41%E
  • Operating ScoreB
    • Turnover0.82B
  • Debt ScoreD
    • Gearing Ratio73.36%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Molecular Templates Co & Affiliate Commenced Chapter 11 Cases As DIP

    Molecular Templates Inc (MTEMQ.PK):MOLECULAR TEMPLATES INC: ON APRIL 20, CO & AFFILIATE COMMENCED CHAPTER 11 CASES AS DIPMOLECULAR TEMPLATES INC - ON APRIL 22, BANKRUPTCY COURT APPROVES DEBTOR-IN-POSSESSION FINANCING - SEC FILINGMOLECULAR TEMPLATES: BANKRUPTCY COURT AUTHORIZED CO TO OBTAIN, POST-PETITION FINANCING ON SENIOR SECURED SUPER-PRIORITY BASIS FROM K2

    Reuters·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%
    Reuters·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%

    Molecular Templates Announces Leadership Changes and Operational Wind Down

    Molecular Templates (MTEM) has announced significant leadership changes, including multiple resignations from its Board of Directors and Dr. Eric E. Poma's resignation from executive roles. This is part of a strategic decision to wind down operations, with Craig Jalbert appointed as the sole director for oversight. The company warns stakeholders about the speculative nature of its securities, suggesting current trading prices may not reflect true value, and investors may not see returns. Molecular Templates focuses on developing targeted biologic therapeutics in the biotechnology sector.

    Tip Ranks·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%
    Tip Ranks·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%

    Why Molecular Templates ( MTEM ) Stock Is Down 60%

    Molecular Templates shares are trading lower by 60% during Friday's session. The company announced it received a Nasdaq delisting notice. Molecular Templates Inc MTEM shares are trading lower by 60% to 13 cents during Friday's session after the company announced it received a Nasdaq delisting ...

    Benzinga·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%
    Benzinga·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%

    Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

    Molecular Templates, Inc. has been notified by Nasdaq of its delisting due to being classified as a "public shell" and failing to comply with listing rules, including not filing its quarterly report and maintaining a required bid price. Trading of its common stock will be suspended on December 26, 2024. The company does not plan to appeal this decision and warns investors about the speculative nature and risks associated with its securities.

    Benzinga·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%
    Benzinga·
    US
    MTEM
    0.00%
    US
    MTEMQ
    0.00%
    © 2025 Longbridge｜Disclaimer